Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies

PURPOSE: Parallel activation of the phosphatidylinositol 3-kinase–mammalian target of rapamycin pathway represents a mechanism of primary and acquired resistance to BRAF-targeted therapy, but the two pathways have yet to be cotargeted in humans. We performed a phase I study to evaluate the safety an...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Subbiah, Vivek, Sen, Shiraj, Hess, Kenneth R., Janku, Filip, Hong, David S., Khatua, Soumen, Karp, Daniel D., Munoz, Javier, Falchook, Gerald S., Groisberg, Roman, Tsimberidou, Apostolia M., Sherman, Steven I., Hwu, Patrick, Meric-Bernstam, Funda
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
Original Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7446411/
https://ncbi.nlm.nih.gov/pubmed/32913986
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00189
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados